Financial News
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
3,850 articles
📰
CSLLY vs. ARGX: Which Stock Is the Better Value Option?
CSLLY vs. ARGX: Which Stock Is the Better Value Option?
📰
NVST or SYK: Which Is the Better Value Stock Right Now?
NVST vs. SYK: Which Stock Is the Better Value Option?
📰
NVST or SYK: Which Is the Better Value Stock Right Now?
NVST vs. SYK: Which Stock Is the Better Value Option?
📰
BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair
SEC-Qualified Financial Expert and Life Sciences Veteran Brings 29 Years of Accounting Leadership to the Board SEC-Qualified Financial Expert and...
This Box Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
This Box Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
Michael Burry Says 'Lights Out': Ominous Sign for Stock Market?
Michael Burry's new "Lights Out for Cassandra Unchained" message posted Sunday on X is an ominous signal given his history of going silent just...
📰
Standard Dental Labs Inc. Engages Strategic Advisor to Support Lab Acquisition Strategy
ORLANDO, Fla., March 23, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. ("SDL" or the "Company") today announced it has entered into an...
Why Are Palantir Shares Surging On Monday?
Palantir Technologies Inc. (NASDAQ:PLTR) shares are climbing Monday. The rally follows a mix of geopolitical relief and significant military contract...
TNXP: ~2500 Patients Have Initiated Treatment with Tonmya Following November 2025 Commercial Launch
By David Bautz, PhD
NASDAQ: TNXP
READ THE FULL TNXP RESEARCH REPORT
Business Update
Encouraging Initial Data from Tonmya™ Launch
Following the...
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma
Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth...
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma
Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth...
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma
Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth...
FDA Approves BMY's Opdivo Label Expansion in Classical Hodgkin Lymphoma
Bristol Myers expands Opdivo's reach with new U.S. and EU approvals in Hodgkin lymphoma, strengthening its immunotherapy leadership and growth...
📰
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.
📰
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.
📰
FDA Clears NVO's Higher Dose of Wegovy: Diversify With These Health ETFs
Novo Nordisk's FDA nod for higher-dose Wegovy could boost healthcare ETFs' appeal, offering diversified exposure to the obesity drug market.
Intuitive Surgical vs. Stryker: Which Surgical Tech Stock Leads?
ISRG outpaces SYK with stronger growth, robotic surgery dominance, and recurring revenue strength, highlighting its edge in MedTech innovation and...
Intuitive Surgical vs. Stryker: Which Surgical Tech Stock Leads?
ISRG outpaces SYK with stronger growth, robotic surgery dominance, and recurring revenue strength, highlighting its edge in MedTech innovation and...
Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?
CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.
Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?
CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.
Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?
CAH sees GLP-1 drugs boost revenue growth, but margins lag as strong demand lifts volumes without significantly improving profitability.
FuelCell Energy Eyes Data Center Gold Rush With Rapid-Deploy Power Blocks
FuelCell Energy Inc. (NASDAQ:FCEL) shares rose Monday after the company introduced a standardized 12.5-megawatt on-site power solution aimed at...
This APA Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades...
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26
By David Bautz, PhD
NASDAQ: DWTX
READ THE FULL DWTX RESEARCH REPORT
Business Update
143 Patients Enrolled in Phase 2b Trial of Halneuron® in CINP;...
DWTX: 143 Patients Enrolled in Phase 2b Trial of Halneuron®; Results Expected in 3Q26
By David Bautz, PhD
NASDAQ: DWTX
READ THE FULL DWTX RESEARCH REPORT
Business Update
143 Patients Enrolled in Phase 2b Trial of Halneuron® in CINP;...
📰
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - RGRD Law
<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" />
<p>SAN...
📰
Roche eröffnet neues Forschungsgebäude für das Institute of Human Biology und leistet damit Pionierarbeit im Bereich menschlicher Modellsysteme, um Entwicklung von Medikamenten zu beschleunigen
Basel, 23. März 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) hat heute die Einweihung des neuen Forschungsstandorts des Institute of Human Biology...
📰
Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development
Basel, 23 March 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the inauguration of the new research home for the Institute of Human...
Hims & Hers Expands Integrated Digital Healthcare Ecosystem
HIMS builds a seamless digital healthcare ecosystem, expanding into diagnostics, global markets and specialty care to reshape access and delivery.
Hims & Hers Expands Integrated Digital Healthcare Ecosystem
HIMS builds a seamless digital healthcare ecosystem, expanding into diagnostics, global markets and specialty care to reshape access and delivery.
Hims & Hers Expands Integrated Digital Healthcare Ecosystem
HIMS builds a seamless digital healthcare ecosystem, expanding into diagnostics, global markets and specialty care to reshape access and delivery.
📰
Sisram Medical Reports Solid Growth in 2025
Solid growth driven by strong performance in international markets, with the injectables business accelerating rapidlyDAXXIFY shows promising results...
📰
Sisram Medical Reports Solid Growth in 2025
Solid growth driven by strong performance in international markets, with the injectables business accelerating rapidly DAXXIFY shows promising...
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Novo Nordisk faces slowing growth and rising competition, while Structure Therapeutics shows strong obesity study results, highlighting a clash of...
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Novo Nordisk faces slowing growth and rising competition, while Structure Therapeutics shows strong obesity study results, highlighting a clash of...
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
Novo Nordisk faces slowing growth and rising competition, while Structure Therapeutics shows strong obesity study results, highlighting a clash of...
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer
GSK secures Japan orphan drug status for risvutatug rezetecan in SCLC, adding to multiple global designations backed by promising early data.
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer
GSK secures Japan orphan drug status for risvutatug rezetecan in SCLC, adding to multiple global designations backed by promising early data.
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer
GSK secures Japan orphan drug status for risvutatug rezetecan in SCLC, adding to multiple global designations backed by promising early data.
GSK's Risvutatug Rezetecan Gets Japan Orphan Drug Tag for Lung Cancer
GSK secures Japan orphan drug status for risvutatug rezetecan in SCLC, adding to multiple global designations backed by promising early data.
Snowflake Cuts Entire Team — Joins Amazon, Canva in AI Push
Last week, data warehousing giant Snowflake Inc. (NYSE:SNOW) reportedly laid off its entire technical writing and documentation department.
The...
Why Are SoFi Technologies Shares Trading Higher On Monday?
SoFi Technologies Inc (NASDAQ:SOFI) shares are gaining ground Monday morning. The digital lender is recovering from a volatile week.
Bearish...
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
Valneva SE (NASDAQ:VALN) shares were falling on Monday following the announcement of topline results from the Phase 3 VALOR clinical trial for its...
Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive
Valneva SE (NASDAQ:VALN) shares were falling on Monday following the announcement of topline results from the Phase 3 VALOR clinical trial for its...
ECL to Boost Data Center AI Cooling Platform With CoolIT Acquisition
Ecolab's $4.75B CoolIT deal boosts its AI data center cooling push, expanding into high-growth liquid cooling and unlocking recurring revenue...